Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine (Nasdaq-bound) announced a definitive merger in a stock deal, with the combined company to trade on Nasdaq as Scipher Medicine Corporation under ticker “SCIP”. The focus will be advancing nebokitug, an anti-CCL24 antibody, into a Phase 2 RA trial, with topline results expected in H1 2028. A $30M private placement is planned, valuing the deal at $150M pre-placement, and cash is expected to fund operations into H2 2028.
How this was made
The 30-second read
Why it matters
The merger creates a new combined company focused initially on advancing nebokitug into a Phase 2 rheumatoid arthritis trial using AI-enabled patient selection, supported by a $30M gross financing and cash runway into H2 2028.
Market read
Definitive M&A terms, financing, and a specific clinical development plan provide a concrete catalyst for biotech deal and clinical-risk pricing.
What to watch
Key execution risks remain: Phase 2 endpoint success, PrismRA test performance in guiding enrollment, and merger closing conditions including S-4 effectiveness and redomiciling.
Background
Chemomab and Scipher announced a definitive merger agreement to combine Chemomab’s clinical-stage anti-CCL24 antibody nebokitug with Scipher’s AI Network Medicine and PrismRA precision medicine test.
Ticker impact
Chemomab entered a definitive merger agreement with Scipher in a stock transaction, with Chemomab holders expected to own ~32% post-merger.
Likely positive bias while deal approval and financing details remain intact; volatility around shareholder vote and S-4 effectiveness.
The article discloses a definitive merger, ownership percentages, and a $30M financing supporting runway, all of which are direct deal-risk drivers for CMMB.
Market effects
Highlights continued capital formation and consolidation in precision medicine and immunology, with AI-driven patient selection as a differentiator.
Israel and US biotech collaboration underscores cross-border deal activity in small/mid-cap biotech.
Nebokitug’s RA Phase 2 timeline and CMS-approved PrismRA test may influence global investor appetite for biomarker-guided immunology programs.
Counterpoint
The deal may be more about platform monetization and financing runway than near-term clinical probability, given the long path to H1 2028 readout.
Key entities
- public_companyChemomab Therapeutics
Nasdaq-listed company (CMMB) entering a definitive stock merger with Scipher to advance nebokitug.
- public_companyScipher Medicine Corporation
Precision medicine company providing AI Network Medicine platform and PrismRA test; post-merger expected to trade as SCIP.
- drug_candidatenebokitug
First-in-class anti-CCL24 antibody intended for a Phase 2 RA trial with AI-guided enrollment.
- diagnostic_testPrismRA
CMS-approved molecular signature test used to predict RA treatment response and guide patient selection.
